Lexaria extends pharmaceutical partnership agreement through April 2026

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. AVGO
2. CDNS
3. SSD
4. JBLU
5. ANT
6. META
7. PECO
8. AGYS
9. NVDA
10. BA

Go back to Lexaria extends pharmaceutical partnership agreement through April 2026

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

November 12, 2025 9:10 AM EST

KELOWNA, BC / ACCESS Newswire / November 12, 2025 / Lexaria Bioscience Corp. (Nasdaq: LEXX)(Nasdaq: LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this update on the Material Transfer Agreement ("MTA") originally entered into on September 4, 2024 with a pharmaceutical company ("PharmaCO") to evaluate Lexaria's DehydraTECHTM technology in a pre-clinical setting.

The original agreement has been extended through April 30, 2026, to accommodate time needed for PharmaCO's... More